Nicole LaForest is a Registered and Licensed Veterinary Technician serving as the current President of the Washington State Association
of Veterinary Technicians. She spends a majority of her time managing Mayo Veterinary Services, the largest specialty, ambulatory practice in the US; based out of the Seattle Area and primarily specializing in orthopedics and regenerative medicine therapies. Nicole currently holds degrees in Human Healthcare Management, Psychology and Veterinary Medicine. She is also the founding member and President of the Academy of Veterinary Technicians in Regenerative Medicine (AVTRM), an organization committed to making Regenerative Medicine a specialty in veterinary medicine
Abstract
The use of stem cell therapeutics has become one of the largest areas of scientific research around the globe. It was first introduced into equine practice in 1995 with the injection of bone marrow derived cells into tendon injuries. The use of stem cell in canine bone marrow transplants date back as early as the 1960’s. Since, it has found great interest in its use in small animals and humans for many different medical conditions, in particular osteoarthritis. It is estimated that 10 to 12 million dogs in the US are affected with osteoarthritis, and it is the most common cause of chronic pain. Stem cells are unspecialized cells capable of self-renewal and differentiation into a specialized cell, and perhaps any type of tissue in the body that is needed. Another term for regenerative medicine is Prolotherapy. Prolotherapy is a regenerative injection treatment used to stimulate the healing mechanism to repair damaged or injured areas in the spine and joints. This term may be inclusive of both stem cell therapy and platelet rich plasma. Both treatment modalities can be used in conjunction to serve as a transport to the intended treatment area. Regenerative medicine therapies should only be implemented or recommended following a thorough examination with a Veterinarian. Diagnostic imaging and further treatment options should be discussed prior to starting prolotherapy as it is known to be contraindicated in the presence of cancer, infection, coagulopathies, NSAID’s and steroids. The patients are monitored closely before, during and after initiating treatment for any adverse effects. By routinely tracking our patients closely with examinations, surveys and all otherwise client communications; we are able to adjust their therapies as needed and determine the patients progress.